What is A (Agilent Technologies) average time for price targets to be met?

On average it took 258 days for the stock forecasts to be reached, with an average price target met ratio of 76.88%.

Which analyst has the most public recommendations on A (Agilent Technologies)?

Dan Leonard works at RBC and has 25 price targets and 17 ratings on A

Which analyst is the currently most bullish on A (Agilent Technologies)?

Patrick Donnelly with the highest potential upside of $48.99

Which analyst is the currently most reserved on A (Agilent Technologies)?

Jonathan Groberg with the lowest potential downside of -$117.78

Agilent Technologies (A) - Analyst Price Targets & Ratings History

A - Agilent Technologies - Stock Forecast

Healthcare - Sector

Coverage Profile Stock analysts Price Targets & Ratings Chart Insider Trading

A is currently covered by 16 analysts with an average price target of $168.67. This is a potential upside of $0.89 (0.53%) from yesterday's end of day stock price of $167.78.

Agilent Technologies's activity chart (see below) currently has 485 price targets and 339 ratings on display. The stock rating distribution of A is 14.81% HOLD and 85.19% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 76.88% with an average time for these price targets to be met of 257.59 days.

Highest price target for A is $190, Lowest price target is $140, average price target is $168.67.

Most recent stock forecast was given by DAN LEONARD from RBC on 27-Aug-2026.

Overview

Agilent Technologies is a company that offers a wide range of application-focused solutions to the life sciences, diagnostics, and applied chemical.

The company operates through three segments, namely, Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab.

The Life Sciences and Applied Markets segment

Offers a range of analytical instruments and solutions to scientists and researchers in the fields of liquid and gas chromatography, mass spectrometry, atomic absorption, and plasma spectroscopy.

The segment’s portfolio includes liquid chromatography systems, gas chromatography systems, inductively coupled plasma mass spectrometry instruments, atomic absorption instruments, microwave plasma-atomic emission spectrometry instruments, inductively coupled plasma optical emission spectrometry instruments, and raman spectroscopy.

The segment also offers cell analysis plate-based assays, flow cytometers, real-time cell analyzers, cell imaging systems, microplate readers, laboratory software, information management and analytics, laboratory automation and robotic systems, dissolution testing, vacuum pumps, and measurement technologies.

The Diagnostics and Genomics segment

Offers a range of products and services for molecular and clinical diagnostics including:

DNA mutation, genotyping, gene copy number, gene rearrangements.
DNA methylation, gene expression, next-generation sequencing, target enrichment, interpretation support software.
Immunohistochemistry in situ hybridization, hematoxylin, eosin, and special staining.
software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry.
Liquid-based pharmacodiagnostics.

The Agilent CrossLab segment

Provides a range of products and services to support laboratory operations and research, including:

GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies.
Startup, operational, training, compliance support, software as a service, asset management, and consultation services.

History

The company was incorporated in 1999 and is headquartered in Santa Clara, California.